Skip to main content
. 2010 May 29;34(9):2090–2097. doi: 10.1007/s00268-010-0639-5

Fig. 1.

Fig. 1

Progression-free survival in high risk gastrointestinal stromal tumor (GIST) patients treated with downsizing tyrosine kinase inhibitor (TKI) until function-sparing surgery was expected (mean duration 4.9 months) prior to R0 resection of the primary followed by adjuvant TKI, compared with historical controls treated with surgery only (**p < 0.01). Start date for survival was the date of diagnosis